Acute Lymphoblastic Leukemia | Topics

FDA Grants Fast Track and Rare Pediatric Disease Designation to WU-CART-007 in R/R T-Cell ALL/LBL
July 20, 2022

WU-CART-007 was granted fast track and rare pediatric disease designation by the FDA for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

Recap: Fellows at MSK and Moffitt ‘Face Off’ to Discuss Treatment Strategies in Older Patients With ALL
July 04, 2022

In a new series from CancerNetwork®, 2 teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.

Ph– B-Cell ALL Achieves MRD Negativity With Inotuzumab Plus Hyper-CVAD and Blinatumomab
June 04, 2022

Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.

Cross Q&A: The Memorial Sloan-Kettering Mavericks
May 27, 2022

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Outcome Determination for Adolescents and Young Adults with ALL
May 27, 2022

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase in Adults with Ph-ALL
May 27, 2022

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study
May 23, 2022

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

Cross Q&A: Team Moffitt Marrowvingians
May 23, 2022

The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.

Adolescent and Young Adult ALL and AML Survivors Exhibit Worse Long-Term Survival vs General Population
May 13, 2022

Leukemia survivors who were adolescents or young adults had worse long-term survival outcomes vs the general population.

Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists
May 13, 2022

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.